Literature DB >> 14554254

Characterization of experimental equine glanders.

Jose Lopez1, John Copps, Catherine Wilhelmsen, Richard Moore, Julie Kubay, Marcel St-Jacques, Stacey Halayko, Christiaan Kranendonk, Shannon Toback, David DeShazer, David L Fritz, Marina Tom, Donald E Woods.   

Abstract

Considerable advances in understanding of the disease caused by Burkholderia mallei have been made employing a combination of tools including genetic techniques and animal infection models. The development of small animal models has allowed us to assess the role of a number of putative virulence determinants in the pathogenesis of disease due to B. mallei. Due to the difficulties in performing active immunization studies in small animals, and due to the fact that the horse is the target mammalian species for glanders, we have initiated experimental studies on glanders in horses. Intratracheal deposition of B. mallei produced clinical glanders with organisms being recovered from tissues of infected horses. The model should prove to be of considerable value in our ongoing studies on the pathogenesis and vaccine development for glanders.

Entities:  

Mesh:

Year:  2003        PMID: 14554254     DOI: 10.1016/j.micinf.2003.07.004

Source DB:  PubMed          Journal:  Microbes Infect        ISSN: 1286-4579            Impact factor:   2.700


  15 in total

1.  Burkholderia mallei cluster 1 type VI secretion mutants exhibit growth and actin polymerization defects in RAW 264.7 murine macrophages.

Authors:  Mary N Burtnick; David DeShazer; Vinod Nair; Frank C Gherardini; Paul J Brett
Journal:  Infect Immun       Date:  2009-11-02       Impact factor: 3.441

2.  Inactivation of Burkholderia mallei in Equine Serum for Laboratory Use.

Authors:  Lorraine Perrett; Ian Mawhinney
Journal:  J Clin Microbiol       Date:  2015-02-11       Impact factor: 5.948

3.  Burkholderia xenovorans LB400 harbors a multi-replicon, 9.73-Mbp genome shaped for versatility.

Authors:  Patrick S G Chain; Vincent J Denef; Konstantinos T Konstantinidis; Lisa M Vergez; Loreine Agulló; Valeria Latorre Reyes; Loren Hauser; Macarena Córdova; Luis Gómez; Myriam González; Miriam Land; Victoria Lao; Frank Larimer; John J LiPuma; Eshwar Mahenthiralingam; Stephanie A Malfatti; Christopher J Marx; J Jacob Parnell; Alban Ramette; Paul Richardson; Michael Seeger; Daryl Smith; Theodore Spilker; Woo Jun Sul; Tamara V Tsoi; Luke E Ulrich; Igor B Zhulin; James M Tiedje
Journal:  Proc Natl Acad Sci U S A       Date:  2006-10-09       Impact factor: 11.205

4.  Burkholderia thailandensis oacA mutants facilitate the expression of Burkholderia mallei-like O polysaccharides.

Authors:  Paul J Brett; Mary N Burtnick; Christian Heiss; Parastoo Azadi; David DeShazer; Donald E Woods; Frank C Gherardini
Journal:  Infect Immun       Date:  2010-11-29       Impact factor: 3.441

Review 5.  Strategies toward vaccines against Burkholderia mallei and Burkholderia pseudomallei.

Authors:  Sara K Bondi; Joanna B Goldberg
Journal:  Expert Rev Vaccines       Date:  2008-11       Impact factor: 5.217

6.  Structural flexibility in the Burkholderia mallei genome.

Authors:  William C Nierman; David DeShazer; H Stanley Kim; Herve Tettelin; Karen E Nelson; Tamara Feldblyum; Ricky L Ulrich; Catherine M Ronning; Lauren M Brinkac; Sean C Daugherty; Tanja D Davidsen; Robert T Deboy; George Dimitrov; Robert J Dodson; A Scott Durkin; Michelle L Gwinn; Daniel H Haft; Hoda Khouri; James F Kolonay; Ramana Madupu; Yasmin Mohammoud; William C Nelson; Diana Radune; Claudia M Romero; Saul Sarria; Jeremy Selengut; Christine Shamblin; Steven A Sullivan; Owen White; Yan Yu; Nikhat Zafar; Liwei Zhou; Claire M Fraser
Journal:  Proc Natl Acad Sci U S A       Date:  2004-09-17       Impact factor: 11.205

7.  Genome sequence alterations detected upon passage of Burkholderia mallei ATCC 23344 in culture and in mammalian hosts.

Authors:  Claudia M Romero; David DeShazer; Tamara Feldblyum; Jacques Ravel; Donald Woods; H Stanley Kim; Yan Yu; Catherine M Ronning; William C Nierman
Journal:  BMC Genomics       Date:  2006-09-05       Impact factor: 3.969

8.  Comparison of the in vitro and in vivo susceptibilities of Burkholderia mallei to Ceftazidime and Levofloxacin.

Authors:  Barbara M Judy; Gregory C Whitlock; Alfredo G Torres; D Mark Estes
Journal:  BMC Microbiol       Date:  2009-05-09       Impact factor: 3.605

9.  Burkholderia Hep_Hag autotransporter (BuHA) proteins elicit a strong antibody response during experimental glanders but not human melioidosis.

Authors:  Rachaneeporn Tiyawisutsri; Matthew T G Holden; Sarinna Tumapa; Sirirat Rengpipat; Simon R Clarke; Simon J Foster; William C Nierman; Nicholas P J Day; Sharon J Peacock
Journal:  BMC Microbiol       Date:  2007-03-15       Impact factor: 3.605

10.  Inactivation of [Fe-S] metalloproteins mediates nitric oxide-dependent killing of Burkholderia mallei.

Authors:  Jessica Jones-Carson; James Laughlin; Mohammed A Hamad; Amanda L Stewart; Martin I Voskuil; Andrés Vázquez-Torres
Journal:  PLoS One       Date:  2008-04-09       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.